Xenon net loss widens 30.7% to $110.74 million in Q2 FY26

Reuters2026/08/06 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.
RD costs rose to USD 99.2 million from USD 75 million, driven by Phase 3 azetukalner programs, Phase 1 pain studies, manufacturing, headcount.
GA spending climbed to USD 23.9 million from USD 19.2 million, on higher headcount plus professional and consulting fees.
Other income increased to USD 11.8 million from USD 8.9 million, reflecting higher interest income.
Cash, cash equivalents, marketable securities totaled USD 1.25 billion; NDA for azetukalner in focal onset seizures remains on track for Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONECNPR____9805554) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xenon net loss widens 30.7% to $110.74 million in Q2 FY26

You may also like

Crypto prices